Allogene Therapeutics, Inc.
ALLO
$1.78
-$0.08-4.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.16% | -9.78% | 6.26% | 18.73% | 14.72% |
| Total Depreciation and Amortization | -7.81% | -6.15% | -1.29% | -0.29% | 0.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.49% | 1.17% | -4.61% | -20.67% | -7.97% |
| Change in Net Operating Assets | -97.45% | 9,194.55% | -39.31% | 93.52% | 73.04% |
| Cash from Operations | -147.78% | 53.21% | 7.04% | 23.94% | 26.26% |
| Capital Expenditure | -1,566.67% | -- | 100.00% | -452.27% | 55.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -398.36% | -188.00% | 176.01% | -72.25% | 599.27% |
| Cash from Investing | -398.71% | -188.03% | 181.63% | -72.77% | 609.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 789.46% | 168.76% | 142.86% | 113.74% | -85.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | 6.21% |
| Cash from Financing | 789.46% | 168.76% | 142.86% | -36.20% | -63.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 138.90% | -254.11% | 195.56% | -246.98% | 130.15% |